Eton Pharmaceuticals (NASDAQ:ETON) Insider David Krempa Sells 19,679 Shares of Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 19,679 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $31.47, for a total value of $619,298.13. Following the transaction, the insider owned 25,249 shares in the company, valued at $794,586.03. This trade represents a 43.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

David Krempa also recently made the following trade(s):

• On Friday, May 22nd, David Krempa sold 42,797 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $33.39, for a total value of $1,428,991.83.
• On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.49, for a total value of $1,181,630.76.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock opened at $32.40 on Thursday. The company has a quick ratio of 0.88, a current ratio of 1.21 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $887.44 million, a P/E ratio of -462.79 and a beta of 0.82. The stock’s 50 day moving average is $26.59 and its 200 day moving average is $20.03. Eton Pharmaceuticals, Inc. has a twelve month low of $13.09 and a twelve month high of $35.66.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.05). The company had revenue of $24.27 million during the quarter, compared to analysts’ expectations of $22.31 million. Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%. On average, equities research analysts predict that Eton Pharmaceuticals, Inc. will post 0.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ETON shares. HC Wainwright upped their price target on Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Craig Hallum upped their price target on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, March 20th. Zacks Research cut Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 17th. B. Riley Financial upped their price objective on Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $41.00.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ETON. Quarry LP bought a new position in Eton Pharmaceuticals in the 3rd quarter valued at approximately $37,000. Legal & General Group Plc bought a new position in shares of Eton Pharmaceuticals during the 2nd quarter valued at $41,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Eton Pharmaceuticals during the 4th quarter valued at $44,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Eton Pharmaceuticals during the 4th quarter valued at $74,000. Finally, SG Americas Securities LLC bought a new position in shares of Eton Pharmaceuticals during the 4th quarter valued at $109,000. 27.86% of the stock is owned by institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.